Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Thenorth1990on Nov 02, 2021 3:17pm
117 Views
Post# 34078758

RE:Shareholders Beware

RE:Shareholders BewareHey TB, Weren't you all excited and saying September was going to be huge ?? And they said Nasdaq listing was priority back in March and reverse split is the only way unless the share price goes up 1000% which we knew won't happen. I understand everyone was hoping for a new face as ceo , but if they have been heading the company until this stage why would they give up their positions at this time when prospects are high. End of the day funding from Boston still exists and I am quite sure they won't let our management to do stuff which is not in their best interest. And I do believe that the independent agency was paid to say what they said. Again what I don't understand is we are not doing a reverse split to save ourselves from a delisting or anything and if the market cap is not gonna change, why does it matter about the ratio. I like having 6 digit shares but still .. just help me understand
<< Previous
Bullboard Posts
Next >>